RELEVENT Trial: Phase II Trial of Ramucirumab, Carboplatin, and Paclitaxel in Previously Untreated Thymic Carcinoma/B3 Thymoma With Area of Carcinoma.

RELEVENT Trial: Phase II Trial of Ramucirumab, Carboplatin, and Paclitaxel in Previously Untreated Thymic Carcinoma/B3 Thymoma With Area of Carcinoma. Clin Lung Cancer. 2018 09; 19(5):e811-e814.

View in: PubMed

subject areas

Adolescent
Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols
Carboplatin
Female
Follow-Up Studies
Humans
Male
Middle Aged
Paclitaxel
Prognosis
Research Design
Thymoma
Thymus Neoplasms
Young Adult

authors with profiles

Marina Chiara Garassino